NEW YORK (GenomeWeb) – Biotech firm X-Chem today announced a multi-target collaboration with Pfizer for the potential development of new treatments for inflammatory and orphan diseases.

X-Chem will apply its discovery engine to identify new leads for several of Pfizer's treatment development programs. Pfizer has an exclusive option to license compounds generated from the collaboration. Further details of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.